Overview
- The UK Government announced £650,000 in initial funding, with Glasgow University, IQVIA and Novo Nordisk partnering on the study.
- Up to 5,000 adults in the most deprived areas of Scotland are slated to be offered free Wegovy, with the programme due to launch next year.
- Researchers will track weight loss, quality of life, obesity‑related illness, NHS use, healthcare costs, and effects on work and sick leave.
- Most participants are expected to receive active medication with a placebo control for others, according to reporting.
- The project, described as the Scotland CardioMetabolic Impact Study (SCoMIS), targets communities where obesity rates are highest and NHS access to such drugs has been limited.